Clinical Trials
2
Active:1
Completed:1
Trial Phases
1 Phases
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 2
2 (100.0%)Effect of Mizagliflozin Repeat Dosing on Adverse Events and Postprandial Glucose Excursions
Phase 2
Active, not recruiting
- Conditions
- Postbariatric Hypoglycemia
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-02-10
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Vogenx, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT05721729
- Locations
- 🇺🇸
Stanford, Palo Alto, California, United States
🇺🇸University of Colorado / Anschutz Medical Campus, Aurora, Colorado, United States
Effect of Mizagliflozin on Postprandial Glucose and Insulin in Post-Bariatric Hypoglycemia Subjects
- First Posted Date
- 2022-09-15
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Vogenx, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT05541939
- Locations
- 🇺🇸
Stanford, Palo Alto, California, United States
🇺🇸University of Colorado / Anschutz Medical Campus, Aurora, Colorado, United States
News
No news found